University of Leicester researcher in potential medical breakthrough
“This new drug could be a game changer for future treatment of asthma” – Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester
The first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.
The research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as “a game changer for future treatment of asthma.”
Three people die every day because of asthma attacks and research shows that two thirds of asthma deaths are preventable, according to Asthma UK.
Fevipiprant (QAW039) significantly decreased the symptoms of asthma, improved lung function, reduced inflammation and repaired the lining of airways.
The drug is currently being evaluated in late stage clinical trials for efficacy in patients with severe asthma, according to ClinTrials.gov.
A total of 61 people took part in the research. One group was given 225mg of the drug twice a day for 12 weeks and the other participants were assigned to a placebo group. Fevipiprant and the placebo were added to the medications the participants were already taking.
The study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.
The sputum eosinophil is an inflammation measurement of a white blood cell that increases in asthma and is used to assess the severity of this condition.
People who do not have asthma have a percentage of less than one and those with moderate-to-severe asthma typically have a reading of about five per cent.
The rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.
Professor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.
Professor Brightling said: “A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.
“Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.
“We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.
“This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a ‘game changer’ for future treatment.”
Gaye Stokes from Grantham in Lincolnshire has had severe asthma for 16 years. She took part in the trial and was part of the Fevipiprant group.
The 54-year-old said: “I knew straight away that I had been given the drug. I felt like a completely different person. I had more get up and go, I was less wheezy and for the first time in years I felt really, really well.
“For me, it felt like a complete wonder drug and I can’t wait for it to be available because I really think it could make a huge difference to me.”
After the 12 week trial and Gaye stopped receiving the drug, she said her health started to “go downhill again very quickly”.
Professor Brightling added that the latest advance underpinned the work of the Leicester Precision Medicine Institute, a Centre of Excellence that coalesces and aligns the research missions of the University of Leicester and the NHS in Leicester.
Future treatment of human disease will increasingly move from a ‘one size fits all’ approach to one of tailoring the treatment to the individual patient.
Asthma is a long-term condition that affects the airways. When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.
The NIHR Leicester Respiratory Biomedical Research Unit – a partnership between the University of Leicester and Leicester’s Hospitals – focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).
The Latest on: Asthma pill
via Google News
The Latest on: Asthma pill
- Hot weather and asthma: Does hot weather make asthma worse?on August 8, 2020 at 8:17 am
HOT weather can make many existing illnesses related to the heart or the lungs much worse. Does hot weather affect asthma?
- Aerobic Training May Improve Asthma Control and Reduce Frequency of Rescue Medication Useon August 6, 2020 at 7:12 am
While both aerobic training and breathing exercises presented similar results for some aspects of asthma control, those undergoing ae ...
- Combination asthma medication is over-prescribed to Australian children—but dispensing patterns are improvingon August 6, 2020 at 6:31 am
Australian children—preschoolers in particular—are being inappropriately prescribed fixed dose combination (FDC) asthma medication, a UNSW Sydney big data study on asthma dispensing patterns has shown ...
- Bladder weakness and leaks are more common than asthma: how to treat iton August 6, 2020 at 5:11 am
One third of women and one in 10 men in Ireland suffer from bladder weakness, little accidents or leaks, making it a more common condition than hay fever, asthma or arthritis. Given that bladder ...
- Individual Circadian Clocks Might Be the Next Frontier of Personalized Medicineon August 6, 2020 at 4:05 am
Scientists have found that our internal body clocks vary so greatly that they could form the next frontiers of personalized medicine. By listening more closely to the ticking of our internal clocks, ...
- Asthma Medicine Not Proven as COVID-19 ‘Cure’on August 4, 2020 at 5:19 pm
But the supposed “cure” is an asthma medication, touted by a Texas doctor, that has not yet been proven in clinical trials as an effective treatment for COVID-19 — though researchers are exploring its ...
- Asthma Medications can Improve Strength Performance in Athleteson August 4, 2020 at 2:50 am
ß2-agonists, drugs used for asthma, found to improve sprint and strength performance in athletes who don't have the respiratory condition, according to a review and pooled data analysis, published ...
- Asthma drugs improve performance in healthy non-asthmatic subjectson August 3, 2020 at 4:52 pm
Popular asthma control drugs β2-agonists such as Albuterol, Formoterol, Terbutaline, etc. that are used as inhalers by millions of asthmatics around the world could have power and stamina enhancing ...
- The way to prevent asthma symptoms being misread for Covid-19on August 3, 2020 at 6:54 am
In the UAE, over 14 per cent of residents have asthma and up to one fifth of the population is allergic to something. Adding to which, in what can be a frightening reality for many patients, ...
- Suffolk Launches Asthma Education Campaign 'Know The Difference'on July 30, 2020 at 10:32 am
... adults and 40 percent of children with asthma do not have control of their asthma. Using appropriate medication can significantly improve their condition. "Given the current public health ...
via Bing News